/
BHVN
$14.95-$0.88 (-5.56%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.4B
151M shares
52-week range
$7.48 – $18.57
67% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-82.13
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $4.1M |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$4.1M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $344.7M | $98.5M | $181.5M | $437.1M | $373.3M | $795.9M | $635.1M |
| Operating income | −$479.1M | −$114.5M | −$218.9M | −$567.9M | −$436.1M | −$885.1M | −$745.4M |
| EBITDA | −$479.1M | −$114.4M | −$211.0M | −$568.5M | −$402.6M | −$837.8M | −$727.5M |
| Net income | −$528.8M | −$118.7M | −$213.8M | −$570.3M | −$408.2M | −$846.4M | −$738.8M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -10.91 | -3.31 | -5.97 | -12.75 | -5.73 | -9.28 | -6.86 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-3.00 | $-3.22–$-2.56 | 11 |
| 2027 | $18M | $-2.44 | $-3.19–$-1.61 | 11 |
| 2028 | $83M | $-2.19 | $-4.34–$-0.43 | 15 |
| 2029 | $270M | $-2.11 | $-2.61–$-1.61 | 10 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
www.biohaven.com- Employees
- 274
- IPO / List date
- Sep 23, 2022
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds BHVN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BHVN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BHVN yet.
